何娟,杨婉花

• 1:上海交通大学医学院附属瑞金医院药剂科

摘要(Abstract)：

目的评估万古霉素群体药动学软件(JPKD-vancomycin)在中国人群的预测,并验证其临床应用效果。方法根据万古霉素群体药动学(PPK)研究模型,在JPKD的自定义板块重新定义新的万古霉素药动学模型。利用贝叶斯反馈法方法估算万古霉素药动学参数。收集我院接受万古霉素治疗的住院患者,排除严重肾功能不全者(肌酐清除率<50 m L·min-1)以及合并用药者(甘露醇、多巴胺、多巴酚丁胺、呋塞米),筛选出有调整过万古霉素剂量且有稳态谷浓度测定数据者68例。将患者第1次的万古霉素给药剂量及相关的个体化信息输入JPKD-vancomycin,使用贝叶斯反馈法估算出患者个人的药动学参数,再输入第2次的万古霉素给药剂量,输注时间和给药间隔,由软件依据上述参数预测出更改剂量后的谷浓度数据,计算预测浓度与实测浓度之间的权重偏差(WRES),考察该软件的预测能力,并通过临床病例验证。结果所有患者使用万古霉素后的实际稳态谷浓度为(11.71±5.15)mg·L-1,以JPKD-vancomycin运算后预测的谷浓度为(11.55±5.19)mg·L-1,WRES为(11.6±7.9)%。模型对中国人群的预测能力良好;经临床初步验证,效果较为满意。结论 JPKD-vancomycin对中国人群万古霉素稳态谷浓度有良好的预测能力。本研究建立的JPKD-vancomycin个体化给药模式,有助于指导临床合理用药。

关键词(KeyWords)： 万古霉素;JPKD;群体药动学;贝叶斯反馈法;个体化给药

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 何娟,杨婉花

DOI: 10.19577/j.cnki.issn10074406.2015.01.007

参考文献(References)：

• [1]Liu C,Bayer A,Cosgrove SE,et al.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children[J].Clin Infect Dis,2011,52(3):e18.
• [2]Rybak M,Lomaestro B,Rotschafer JC,et al.Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health-System Pharmacists,the Infectious Diseases Society of America,and the Society of Infectious Diseases Pharmacists[J].Am J Health Syst Pharm,2009,66(1):82.
• [3]佚名.万古霉素临床应用中国专家共识(2011版)[J].中国新药与临床杂志,2011,30(8):561.
• [4]Beibei L,Yun C,Mengli C,et al.Linezolid versus vancomycin for the treatment of gram-positive bacterial infections:meta-analysis of randomised controlled trials[J].Int J Antimicrob Agents,2010,35(1):3.
• [5]Bounthavong M,Hsu DI.Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus(MRSA)complicated skin and soft tissue infection(c SSTI):a meta-analysis[J].Curr Med Res Opin,2010,26(2):407.
• [6]Shorr AF,Kunkel MJ,Kollef M.Linezolid versus vancomycin for Staphylococcus aureus bacteraemia:pooled analysis of randomized studies[J].J Antimicrob Chemother,2005,56(5):923.
• [7]Cai Y,Wang R,Liang B,et al.Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease[J].Antimicrob Agents Chemother,2011,55(3):1162.
• [8]Bliziotis IA,Plessa E,Peppas G,et al.Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections:a meta-analysis[J].Ann Pharmacother,2010,44(1):97.
• [9]Mc Claine RJ,Husted TL,Hebbeler-Clark RS,et al.Meta-analysis of trials evaluating parenteral antimicrobial therapy for skin and soft tissue infections[J].Clin Infect Dis,2010,50(8):1120.
• [10]Pea F,Bertolissi M,Di Silvestre A,et al.TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients[J].Int J Antimicrob Agents,2002,20(5):326.
• [11]Buelga DS,del Mar Fernandez de Gatta M,Herrera EV,et al.Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies[J].Antimicrob Agents Chemother,2005,49(12):4934.
• [12]Elyasi S,Khalili H,Dashti-Khavidaki S,et al.Vancomycin-induced nephrotoxicity:mechanism,incidence,risk factors and special populations.A literature review[J].Eur J Clin Pharmacol,2012,68(9):1243.